In this article, we will list the 5 Best Healthcare AI Stocks to Buy According to Analysts. Please visit 8 Best Healthcare AI Stocks to Buy According to Analysts if you would like to see the extended list and the methodology behind it.

5. AbCellera Biologics Inc. (NASDAQ:ABCL)

On April 22, 2026, JonesResearch highlighted AbCellera Biologics Inc. (NASDAQ:ABCL), noting that if its ABCL635 candidate demonstrates clean safety with no hepatic signals and achieves target engagement comparable to Veohah and Lynkuet, the therapy could be “very competitive.” The firm has reiterated its Buy rating and $11 price target on AbCellera Biologics Inc. (NASDAQ:ABCL) ahead of a Phase 1 update expected on May 11, 2026.

Just earlier in the month of April, JonesResearch analyst Debanjana Chatterjee initiated coverage of AbCellera Biologics Inc. (NASDAQ:ABCL) with a Buy rating and $11 price target on the shares. The firm has said that AbCellera Biologics Inc. (NASDAQ:ABCL)’s antibody discovery platform has advanced 19 molecules into clinical development across both internal and partnered programs spanning multiple therapeutic areas, with its capabilities “best illustrated” through its collaboration with Eli Lilly.

AbCellera Biologics Inc. (NASDAQ:ABCL) develops antibody-based therapies targeting diseases with unmet medical needs.

4. Butterfly Network, Inc. (NYSE:BFLY)

On April 30, 2026, Butterfly Network, Inc. (NYSE:BFLY) reported Q1 EPS of (3c), versus consensus estimates of (5c), while revenue rose to $26.5 million from expectations of $25.74 million. CEO Joseph DeVivo said the company delivered a strong start to the year, with 25% revenue growth and continued improvement in gross margins. He said the business is increasingly organized around three growth engines: global expansion of point-of-care ultrasound, the extension of those capabilities into Home & Community Care, and the growth of Butterfly Embedded, which expands the company’s technology beyond traditional ultrasound into new applications. He added that these initiatives are part of a single platform strategy that is beginning to scale.

Butterfly reaffirmed its full-year 2026 revenue guidance of $117 million to $121 million, compared with consensus estimates of $116.62 million, and continues to expect an adjusted EBITDA loss of $21 million to $25 million.

On April 21, 2026, the company appointed Arun Nagdev as Chief Medical Officer for Point-of-Care Ultrasound. In this role, he will lead global medical strategy for the company’s core POCUS business, including clinical validation, customer engagement, and regulatory development. He currently serves as Director of Emergency Ultrasound at Highland General Hospital and as an Associate Clinical Professor at the University of California, San Francisco.

Butterfly Network, Inc. (NYSE:BFLY) develops handheld ultrasound imaging systems, including its Butterfly iQ+ and iQ3 devices, designed to deliver whole-body imaging through a single probe integrated with mobile and hospital-based workflows.

3. Medtronic plc (NYSE:MDT)

On April 26, 2026, Medtronic announced continued momentum for the Affera family of technologies for cardiac arrhythmia treatment, including promising data presented at the Heart Rhythm Society (HRS) Annual Meeting and the start of a new trial to evaluate a broader population of atrial fibrillation (Afib) patients. Results from the ongoing early feasibility study evaluating the Affera mapping and ablation system and the Sphere-9 catheter for treatment of recurrent sustained monomorphic ventricular tachycardia after a heart attack were presented as a late-breaking clinical trial. Patients treated at centers across the U.S. were followed for six months post-ablation. Results showed 65.5% of patients remaining free from VT recurrence at six months. The U.S. Food and Drug Administration granted Breakthrough Device Designation for the Sphere-9 catheter for the treatment of VT, providing an expedited regulatory pathway for the technology.

At HRS, a new sub-analysis from the Sphere-360 European study demonstrated positive results related to the durability of lesions in AFib procedures in patients with left common pulmonary veins. Results showed 100% lesion durability, highlighting consistency across patients with varied anatomies. Medtronic also announced the first patient enrollment in Conquer-AF, a prospective, multi-center, interventional, non-randomized study to characterize the safety and effectiveness of the Sphere-9 catheter in patients with recurrent paroxysmal or persistent AFib who have previously had an ablation procedure.

On April 23, 2026, Jefferies analyst Matthew Taylor lowered the firm’s price target on Medtronic (MDT) to $95 from $108 and kept a Hold rating on the shares. The firm updated its FY26 EPS outlook to reflect MiniMed (MMED) IPO timing and one-time expenses for MiniMed Flex. Jefferies added that Medtronic’s announced one-time $157M charge in Q4 related to the present value of future payments owed to Blackstone for the MiniMed Flex launch added to the EPS guide revision.

Medtronic plc (NYSE:MDT) develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients in the United States, Ireland, and internationally.

2. Waystar Holding Corp. (NASDAQ:WAY)

On April 29, 2026, Waystar Holding Corp. (NASDAQ:WAY) reported Q1 adjusted EPS of $0.42, ahead of consensus estimates of $0.39, while revenue came in at $313.9 million versus expectations of $311.68 million. CEO Matt Hawkins said the company delivered a solid start to the year, supported by strong execution and continued platform expansion. He noted progress on the Iodine integration, the launch of new offerings including an AI-powered recoupment solution, and bookings that exceeded internal expectations as more healthcare providers standardize on Waystar’s platform.

Waystar reaffirmed its fiscal 2026 outlook, guiding for adjusted EPS of $1.59 to $1.68 compared with consensus estimates of $1.63, and revenue of $1.274 billion to $1.294 billion versus expectations of $1.29 billion.

Following the report, UBS analyst Kevin Caliendo lowered his price target on Waystar Holding Corp. (NASDAQ:WAY) to $37 from $41 while maintaining a Buy rating. The firm said the company posted solid results, with both total and subscription revenue exceeding expectations and EBITDA margins coming in above prior levels and long-term targets, signaling strong underlying profitability. However, UBS noted that unchanged full-year guidance and a slightly softer near-term growth cadence could weigh on sentiment, especially given the company’s history of raising expectations throughout the year.

Waystar Holding Corp. (NASDAQ:WAY) provides cloud-based software solutions that help healthcare providers manage payments, claims, and revenue cycle operations.

1. Intuitive Surgical, Inc. (NASDAQ:ISRG)

On April 23, 2026, Barclays lowered its price target on Intuitive Surgical, Inc. (NASDAQ:ISRG) to $651 from $712 while maintaining an Overweight rating following the company’s Q1 results. The firm said the quarter delivered a “strong fundamental beat,” driven by procedure growth and system placements.

A day earlier, Baird raised its price target on Intuitive Surgical, Inc. (NASDAQ:ISRG) to $610 from $575 and kept an Outperform rating. The firm updated its model after the company’s beat-and-raise quarter, though it cautioned that broader MedTech sentiment could weigh on the stock.

On April 21, 2026, Intuitive Surgical reported Q1 adjusted EPS of $2.50, well above consensus estimates of $2.11, while revenue rose to $2.77 billion from expectations of $2.62 billion. Worldwide procedures across the da Vinci Surgical System and Ion System platforms grew about 17% year over year. Da Vinci procedures increased approximately 16%, while Ion procedures rose around 39%. The company placed 431 da Vinci systems during the quarter, up from 367 a year earlier, including 232 da Vinci 5 systems compared to 147 in the prior-year period. It also placed 52 Ion systems, up from 49 last year.

For full-year 2026, Intuitive Surgical expects da Vinci procedure growth of about 13.5% to 15.5%, a non-GAAP gross margin of 67.5% to 68.5% of revenue, and operating expense growth of 11% to 14%. The margin outlook includes an estimated 1% revenue impact from tariffs.

Intuitive Surgical, Inc. (NASDAQ:ISRG) develops robotic-assisted surgical systems and related technologies aimed at expanding access to minimally invasive care globally.

READ NEXT: 8 Best Beginner Stocks to Buy Right Now and 10 Fastest-Growing Financial Stocks to Invest In

Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.